| Detected | Trial | Change |
|---|---|---|
| 2026-05-23 | NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using… |
Trial completed |
| 2026-05-23 | NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using… |
date change Primary completion moved earlier: 2026-07-31 -> 2026-05-11 |
| 2026-05-23 | NCT03860987 Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using… |
date change Completion moved earlier: 2028-08-01 -> 2026-05-18 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06099093 | Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | Prostate Cancer | Recruiting |
| Phase 2 | |||
| NCT04573231 | Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer | Breast Cancer | Recruiting |
| NCT05155046 | 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body… | Localized Prostate Cancer | Recruiting |
| NCT05616650 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single… | Prostatic Neoplasms | Recruiting |
| NCT03181867 | 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | Prostate Neoplasms | Active, Not Recruiting |
| NCT03976843 | Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | Prostate Cancer | Active, Not Recruiting |
| NCT03173924 | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer | Metastatic Prostate Cancer | Active, Not Recruiting |
| Not specified | |||
| NCT05588128 | Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using… | Prostate Cancer | Recruiting |